Medicago has announced that it will conduct a feasibility study in collaboration with Genopole biopark, in Evry, for the establishment of a vaccine production facility in France.
Subscribe to our email newsletter
Medicago has obtained a grant from the Quebec Ministry of Economic Development, Innovation and Export Trade to finance 40% of the study. The study will be conducted by SNC Lavalin with the assistance of Medicago and the Genopole d’Evry.
Andy Sheldon, president and CEO of Medicago, said: “As we are able to rapidly produce new vaccines in large quantities, we have been in discussions with several countries in Europe, Asia and Africa for the establishment of partnerships to create domestic vaccine production infrastructures based on Medicago’s technologies.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.